AMENDMENTS TO THE CLAIMS

Docket No.: 28967/5794C

This listing of claims will replace all prior versions, and listings, of claims in the applications:

Listing of Claims:

- 1. (Currently amended) A method for activating at least one vascular endothelial growth factor selected from the group consisting of <u>purified VEGF-C</u> and <u>purified VEGF-D</u>, comprising treating said at least one vascular endothelial growth factor with a serine protease.
- 2. (Currently amended) [[A]] The method according to claim 1, wherein the serine protease is plasmin.
- 3. (Currently amended) [[A]] The method according to claim 1, wherein said at least one vascular endothelial growth factor is in an unprocessed form or a partially processed form.
- 4. (Currently amended) [[A]] <u>The</u> method according to claim 1, wherein said vascular endothelial growth factor is VEGF-D.
- 5. (Currently amended) [[A]] <u>The</u> method according to claim 1, wherein said vascular endothelial growth factor is VEGF-C.
 - 6-14. (Canceled)
- 15. (Currently amended) A method of treatment of a disorder selected from the group consisting of coronary artery disease, lymphedema, restenosis and stenosis comprising administering an effective amount of the pharmaceutical composition comprising an effective amount of a serine protease and a pharmaceutically acceptable excipient of claim 14 to a patient in need thereof.
 - 16-17. (Canceled)
 - 18. (New) The method according to claim 2, wherein the plasmin is purified.

Application No. 10/522,232
Amendment dated October 16, 2007

Reply to Office Action of July 16, 2007

selected from the group consisting of VEGF-C and VEGF-D, comprising treating said at least one

(New) A method for activating at least one vascular endothelial growth factor

Docket No.: 28967/5794C

vascular endothelial growth factor with a purified serine protease.

20. (New) The method according to claim 19, wherein said at least one vascular

endothelial growth factor is in an unprocessed form or a partially processed form.

21. (New) The method according to claim 19, wherein said vascular endothelial growth

factor is VEGF-D.

19.

22. (New) The method according to claim 19, wherein said vascular endothelial growth

factor is VEGF-C.

23. (New) The method according to claim 19, wherein the serine protease is plasmin.

24. (New) The method according to claim 15, wherein the composition is administered

to said patient by local administration.

25. (New) The method according to claim 15, wherein the serine protease is plasmin.

9